NeOnc's Global Gambit: A Nasal Spray for Brain Cancer Nears a Key Test

CALABASAS, Calif. – June 23, 2026 – NeOnc Technologies, a clinical-stage biopharmaceutical company, today announced it has secured Investigational New Drug (IND) approval from the Department of Health – Abu Dhabi (DOH) for its lead candidate, NEO100. The therapy, a novel formulation of purified perillyl alcohol administered intranasally, is designed to treat aggressive brain cancers. This authorization is not merely a procedural step; it’s a significant strategic move that expands the company’s global development footprint into the Middle East just weeks before it expects to release pivotal Phase 2 clinical data in the United States.

The UAE approval is remarkably broad, covering three separate clinical trial protocols for adults—from initial Phase 1 safety studies through Phase 2 efficacy trials—as well as a defined pathway for pediatric studies. This allows NeOnc to run multiple stages of clinical development in parallel, potentially accelerating the overall timeline for a therapy aimed at one of oncology's most intractable targets: progressive or recurrent high-grade gliomas.

A Strategic Foothold Ahead of a Crucial Milestone

Securing regulatory clearance in the United Arab Emirates represents a key part of NeOnc's international strategy. The UAE, and Abu Dhabi in particular, is actively working to become a regional hub for life sciences and clinical research, boasting a growing pharmaceutical market projected to reach US$8.0 billion by 2033. Gaining IND status from the DOH allows NeOnc to legally import and test NEO100, tapping into a new patient pool and building a global data package. This approval follows a similar clearance for the company's second major drug platform, NEO212, earlier in the month, cementing a significant clinical presence in the region.

The timing is critical. NeOnc is on the cusp of what its leadership calls "one of the most important clinical milestones in the Company’s history." By the end of July 2026, the company expects to report top-line data from its fully enrolled Phase 2a trial of NEO100 in the U.S. This study focuses on patients with a specific subtype of recurrent brain cancer, IDH1-mutant high-grade glioma.

“This authorization is significant because it comes at a pivotal moment for NeOnc and the NEO100 program,” said Amir Heshmatpour, CEO of NeOnc. He noted that positive results from the upcoming U.S. trial could position NEO100 for additional regulatory opportunities, including a potential Breakthrough Therapy designation from the FDA. The UAE approval provides a powerful parallel track, de-risking development and preparing the company for rapid international expansion should the data prove compelling.

Bypassing the Brain's Ultimate Defense

The core innovation behind NEO100 lies in its elegant solution to a decades-old problem: the blood-brain barrier (BBB). This highly selective, semipermeable border of endothelial cells acts as the brain's primary gatekeeper, protecting it from toxins and pathogens. While essential for survival, it also blocks the vast majority of cancer drugs from reaching tumors in the brain, rendering many systemic chemotherapies ineffective. For decades, clinicians have relied on invasive methods like direct injection or surgery to bypass it.

NEO100 is designed to circumvent this barrier non-invasively. Administered as a simple nasal spray, the therapy leverages the direct anatomical connections between the upper nasal cavity and the brain—the olfactory and trigeminal nerve pathways. This "nose-to-brain" route allows the active ingredient, a purified form of the naturally occurring monoterpene perillyl alcohol, to reach the central nervous system directly, concentrating the therapeutic agent at the tumor site while minimizing systemic exposure and its associated side effects.

“NEO100 uses intranasal delivery to reach the brain directly, a practical route that circumvents the blood-brain barrier without surgery or systemic chemotherapy,” explained Dr. Thomas Chen, NeOnc’s Founder and Chief Medical Officer. The non-invasive nature is a game-changer for patient quality of life and opens up new possibilities for treating vulnerable populations. “Because it is non-invasive, this approach can enable studies in difficult groups, including children with high-grade gliomas that have few options today,” Dr. Chen added. The UAE's authorization of a pediatric pathway is a crucial step toward that goal.

High Stakes in the War on Glioma

The clinical need for a therapy like NEO100 is immense. High-grade gliomas, including Grade IV glioblastoma, are the most common and aggressive primary brain tumors in adults. They are notoriously difficult to treat due to their infiltrative growth, and despite a standard-of-care regimen involving surgery, radiation, and chemotherapy, recurrence is nearly universal. For patients with recurrent disease, the prognosis is dire, with median survival often measured in months and treatment options offering limited benefit.

The upcoming Phase 2a data readout represents the first controlled evaluation of NEO100 in this challenging patient population. Success in the trial could validate the company's entire intranasal delivery platform and offer a desperately needed new option for patients. In the U.S., NEO100 has already received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA, all of which acknowledge the severe unmet need it aims to address.

According to independent medical experts, while preclinical data on perillyl alcohol has been promising, robust human clinical data is the ultimate arbiter of success. The upcoming results will be scrutinized by clinicians, regulators, and investors alike. If the study demonstrates a meaningful improvement over available therapies, NeOnc believes it could support discussions with regulators regarding accelerated development pathways.

As the company prepares for its July data reveal, the UAE approval provides a powerful tailwind. It validates the science and manufacturing on an international stage and lays the groundwork for a global clinical program. For NeOnc, the objective is not just to advance another oncology drug, but to pioneer a new, non-invasive paradigm that could fundamentally alter how diseases of the central nervous system are treated worldwide.